According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Published Date: 09 Jun 2023

Italy: Deep, long-lasting responses and sustained survival seen with fixed-duration ibrutinib plus venetoclax are maintained in high-risk patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

O. A. J. Simpson passes away from cancer.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

ASCO Expert Roundtable: Breast Cancer: Expert Roundtable from the American Society of Clinical Oncology

4.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

5.

After cancer: Study explores caring-healing modalities for survivors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot